DALLAS, March 31, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Sunesis Pharmaceuticals Inc. (Nasdaq:SNSS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/SNSS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Sunesis Pharmaceuticals Inc. (SNSS) is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. As of December 31, 2008, the Company was advancing voreloxin through phase II development. As of December 31, 2008, SNSS was conducting three clinical trials of voreloxin: a phase II clinical trial (known as the REVEAL-1 trial) in previously untreated elderly patients with acute myeloid leukemia (AML), a phase Ib/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and a phase II single agent clinical trial in advanced platinum-resistant ovarian cancer patients. The Company has worldwide development and commercialization rights to voreloxin.
Message Board Search for SNSS: http://www.boardcentral.com/boards/SNSS
In the report, the analyst notes:
"Net loss for the fourth quarter of 2009 was $4.0 million and $40.2 million for the year ended December 31, 2009; net loss for the year included non-cash charges of $21.0 million related to the accounting for a tranched private placement, for which the initial $10.0 million was closed in April 2009 and the second $5.0 million was closed in October 2009.
"Revenues for the three months and year ended December 31, 2009, were $12,500 and $3.8 million, as compared to $12,500 and $5.4 million for the same periods in 2008. The decrease of $1.6 million between the annual periods was primarily due to the completion of research funding and technology access fee amortization under the Biogen Idec collaboration in June 2008…"
To read the entire report visit: http://www.stockpreacher.com/n/SNSS
See what investors are saying about SNSS at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com.
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.